Case Report

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam

Marc Xipell

*Author for correspondence:

E-mail Address: xipell@clinic.cat

Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

Search for more papers by this author

Marta Bodro

Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

Search for more papers by this author

Francesc Marco

Microbiology Department, Hospital Clínic-ISGLOBAL; University of Barcelona, Barcelona, Spain

Search for more papers by this author

José A Martínez

Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

Search for more papers by this author

Alex Soriano

Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

Search for more papers by this author

Published Online:5 Oct 2017https://doi.org/10.2217/fmb-2017-0018

View article

Abstract

Ceftolozane/tazobactam is a novel fifth-generation cephalosporin β-lactamase combination with activity against extended-spectrum β-lactamases-producing enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. However, clinical experience in real cases caused by these microorganisms is scarce. In this study, we describe three patients with severe infections caused by multidrug resistant and extensively drug-resistant (XDR) P. aeruginosa that were successfully treated with ceftolozane/tazobactam.

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1 Morata L, Cobos-Trigueros N, Martínez JA et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 56(9), 4833–4837 (2012).Crossref, Medline, CAS, Google Scholar
2 Huwaitat R, Mccloskey AP, Gilmore BF, Laverty G. Potential strategies for the eradication of multi-drug resistant Gram-negative bacterial infections. Future Microbiol. 11, 955–972 (2016).Link, CAS, Google Scholar
3 Amin AN, Deruelle D. Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiol. 10(6), 1049–1062 (2015).Link, CAS, Google Scholar
4 van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin. Infect. Dis. 63(2), 234–241 (2016). •• Describes the mechanism of action, pharmacokinetics, pharmacodynamics, antimicrobial activity and clinical experience of ceftolozane/tazobactam (C/T).Crossref, Medline, CAS, Google Scholar
5 Buehrle DJ, Shields RK, Chen L et al. Evaluation of the in vitro activity of ceftazidime–avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob. Agents Chemother. 60(5), 3227–3231 (2016). •• One of the first descriptions about testing different strains of Pseudomonas aeruginosa with C/T, comparing them to other agents including ceftazidime/avibactam.Crossref, Medline, CAS, Google Scholar
6 Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J. Antimicrob. Chemother. 72(5), 1386–1395 (2017).Crossref, Medline, CAS, Google Scholar
7 Magiorakos A, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268–281 (2011).Crossref, Medline, Google Scholar
8 Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int. J. Antimicrob. Agents 46(5), 502–510 (2015).Crossref, Medline, CAS, Google Scholar
9 Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, Phase III ceftolozane-tazobactam study. Antimicrob. Agents Chemother. 60(7), 4387–4390 (2016).Crossref, Medline, CAS, Google Scholar
10 Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 61(5), 853–855 (2015).Crossref, Medline, Google Scholar
11 Hernández-Tejedor A, Merino-Vega CD, Martín-Vivas A et al. Successful treatment of multidrug-resistantPseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection 45(1), 115–117 (2016).Crossref, Medline, Google Scholar
12 VanScoy BD, Mendes RE, Castanheira M et al. Relationship between ceftolozane–tazobactamexposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiberinfection model. Antimicrob. Agents Chemother. 58(10), 6024–6031 (2014).Crossref, Medline, Google Scholar

Vol. 12, No. 14

Metrics

Downloaded 244 times

History

Published online 5 October 2017

Published in print November 2017

Information

Keywords

Financial & competing interests disclosure

A Soriano has received honoraria as a speaker from Merck Sharp & Dohme. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Merck Sharp & Dohme provided medical writing support but was not involved in the content of the manuscript.

Informed consent disclosure

The authors state that they have obtained verbal and written informed consent from the patients for the inclusion of their medical and treatment history within this case report.

PDF download